ArticleInfection2026
Post-pandemic resurgence of Mycoplasma pneumoniae and its emerging link with Rhinovirus in children.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Two-Year Pathogen Dynamics, Coinfection Features, and Core Risk Factors Associated With Severe Pediatric Acute Respiratory Tract Infections in Hangzhou, China.Influenza and other respiratory viruses · 2026Observational
- Letter to the Editor on: "Two-Year Pathogen Dynamics, Coinfection Features, and Core Risk Factors Associated With Severe Pediatric Acute Respiratory Tract Infections in Hangzhou, China".Influenza and other respiratory viruses · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMycoplasma pneumoniae (MPP) infections occur regularly every 1 to 3 years. A wave of infections was anticipated around late 2022 to early 2023. However, our data revealed a delayed onset, with a notable increase in cases in 2023/24. This study describes pediatric MPP detections during this resurgence and explores clinical differences between MPP mono-detection and MPP with rhinovirus/enterovirus (RV/EV) co-detection.
methodsWe retrospectively analyzed PCR-confirmed MPP detections in children aged 0-17 years presenting to a tertiary pediatric hospital between 2017 and 2024. Cases from 2017 to 2022 were used as descriptive historical background data (G1, n = 10), while the main analysis focused on the 2023/24 cohort (G2, n = 87). Within this cohort, children with MPP mono-detection were compared with those with MPP plus RV/EV co-detection. Group comparisons were performed using chi-square or Fisher's exact test and t-test or Mann-Whitney U test, as appropriate.
resultsTen sporadic MPP detections occurred between 2017 and 2022, compared with 87 detections in 2023/24, indicating a marked increase in hospital presentations. Because of the small historical group, comparisons with 2023/24 were interpreted descriptively. In the 2023/24 cohort, RV/EV was the most frequent viral co-detection. Compared with children with MPP mono-detection, children with MPP plus RV/EV co-detection were more often male, were less frequently febrile, and showed lower inflammatory parameters, including lower rates of elevated CRP and higher rates of leukopenia and neutropenia.
conclusionIn 2023/24, Mycoplasma pneumoniae infections surged dramatically, accompanied by an unprecedented rise in Rhino/Enterovirus coinfections especially in young, male patients. While these findings highlight a potentially important phenotypic pattern, further prospective studies are needed to clarify causality, temporal sequence, and distinct underlying mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.